CABALETTA BIO, INC. Net Income
CABALETTA BIO, INC. (CABA) reported Net Income of -$51.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-13
- CABALETTA BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$51.02M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$43.52M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$41.92M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$44.87M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for fiscal 2022 was -$52.98M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for fiscal 2021 was -$46.29M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for fiscal 2020 was -$33.34M.
- CABALETTA BIO, INC. net income (loss) attributable to parent for fiscal 2019 was -$16.94M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$51.02M 10-Q · filed 2026-08-13 | -$94.53M 10-Q · filed 2026-08-13 | -$136.46M derived: sum of 3 quarters · filed 2026-08-13 | -$181.32M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$43.52M 10-Q · filed 2026-08-13 | -$85.44M derived: sum of 2 quarters · filed 2026-08-13 | -$130.30M derived: sum of 3 quarters · filed 2026-08-13 | -$175.43M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$41.92M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$86.79M derived: sum of 2 quarters · filed 2026-04-28 | -$131.92M derived: sum of 3 quarters · filed 2026-08-13 | -$167.86M DEF 14A · filed 2026-04-28 | -$167.86M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$44.87M 10-Q · filed 2025-11-10 | -$89.99M derived: sum of 2 quarters · filed 2026-08-13 | -$125.94M 10-Q · filed 2025-11-10 | -$158.52M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$45.13M 10-Q · filed 2026-08-13 | -$81.07M 10-Q · filed 2026-08-13 | -$113.65M derived: sum of 3 quarters · filed 2026-08-13 | -$144.28M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$35.94M 10-Q · filed 2026-08-13 | -$68.53M derived: sum of 2 quarters · filed 2026-08-13 | -$99.15M derived: sum of 3 quarters · filed 2026-08-13 | -$126.76M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2024-12-31 | -$32.58M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$63.21M derived: sum of 2 quarters · filed 2026-04-28 | -$90.81M derived: sum of 3 quarters · filed 2026-04-28 | -$115.86M DEF 14A · filed 2026-04-28 | -$115.86M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$30.63M 10-Q · filed 2025-11-10 | -$58.23M derived: sum of 2 quarters · filed 2025-11-10 | -$83.28M 10-Q · filed 2025-11-10 | -$104.17M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-06-30 | -$27.60M 10-Q · filed 2025-11-10 | -$52.65M 10-Q · filed 2025-08-07 | -$73.54M derived: sum of 3 quarters · filed 2026-04-28 | -$89.99M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-03-31 | -$25.05M 10-Q · filed 2025-11-10 | -$45.94M derived: sum of 2 quarters · filed 2026-04-28 | -$62.39M derived: sum of 3 quarters · filed 2026-04-28 | -$76.87M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2023-12-31 | -$20.89M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$37.34M derived: sum of 2 quarters · filed 2026-04-28 | -$51.83M derived: sum of 3 quarters · filed 2026-04-28 | -$67.68M DEF 14A · filed 2026-04-28 | -$67.67M 10-K · filed 2024-03-21 |
| 2023-09-30 | -$16.45M 10-Q · filed 2024-11-14 | -$30.93M derived: sum of 2 quarters · filed 2024-11-14 | -$46.79M 10-Q · filed 2024-11-14 | -$62.48M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$14.49M 10-Q · filed 2024-11-14 | -$30.34M 10-Q · filed 2024-08-08 | -$46.03M derived: sum of 3 quarters · filed 2024-11-14 | -$57.46M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-03-31 | -$15.85M 10-Q · filed 2024-11-14 | -$31.55M derived: sum of 2 quarters · filed 2024-11-14 | -$42.97M derived: sum of 3 quarters · filed 2024-11-14 | -$55.88M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2022-12-31 | -$15.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$27.12M derived: sum of 2 quarters · filed 2024-03-21 | -$40.03M derived: sum of 3 quarters · filed 2024-03-21 | -$52.98M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$11.43M 10-Q · filed 2023-11-09 | -$24.34M derived: sum of 2 quarters · filed 2023-11-09 | -$37.28M 10-Q · filed 2023-11-09 | -$51.17M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$12.91M 10-Q · filed 2023-11-09 | -$25.86M 10-Q · filed 2023-08-10 | -$39.74M derived: sum of 3 quarters · filed 2023-11-09 | -$51.30M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-03-31 | -$12.95M 10-Q · filed 2023-11-09 | -$26.83M derived: sum of 2 quarters · filed 2023-11-09 | -$38.39M derived: sum of 3 quarters · filed 2023-11-09 | -$49.53M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2021-12-31 | -$13.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$25.45M derived: sum of 2 quarters · filed 2023-03-16 | -$36.59M derived: sum of 3 quarters · filed 2023-03-16 | -$46.29M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$11.56M 10-Q · filed 2022-11-10 | -$22.70M derived: sum of 2 quarters · filed 2022-11-10 | -$32.40M 10-Q · filed 2022-11-10 | -$41.71M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$11.14M 10-Q · filed 2022-11-10 | -$20.84M 10-Q · filed 2022-08-11 | -$30.15M derived: sum of 3 quarters · filed 2022-11-10 | -$38.54M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-03-31 | -$9.70M 10-Q · filed 2022-11-10 | -$19.01M derived: sum of 2 quarters · filed 2022-11-10 | -$27.40M derived: sum of 3 quarters · filed 2022-11-10 | -$35.56M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2020-12-31 | -$9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$17.70M derived: sum of 2 quarters · filed 2022-03-17 | -$25.85M derived: sum of 3 quarters · filed 2022-03-17 | -$33.34M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$8.39M 10-Q · filed 2021-11-01 | -$16.55M derived: sum of 2 quarters · filed 2021-11-01 | -$24.03M 10-Q · filed 2021-11-01 | -$29.43M derived: sum of 4 quarters · filed 2021-11-01 | |
| 2020-06-30 | -$8.15M 10-Q · filed 2021-11-01 | -$15.64M 10-Q · filed 2021-08-05 | -$21.04M derived: sum of 3 quarters · filed 2021-11-01 | -$25.69M derived: sum of 4 quarters · filed 2021-11-01 | |
| 2020-03-31 | -$7.49M 10-Q · filed 2021-11-01 | -$12.89M derived: sum of 2 quarters · filed 2021-11-01 | -$17.54M derived: sum of 3 quarters · filed 2021-11-01 | -$20.90M derived: sum of 4 quarters · filed 2021-11-01 | |
| 2019-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$10.05M derived: sum of 2 quarters · filed 2021-03-16 | -$13.41M derived: sum of 3 quarters · filed 2021-03-16 | -$16.94M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$4.65M 10-Q · filed 2020-11-10 | -$8.01M derived: sum of 2 quarters · filed 2020-11-10 | -$11.54M 10-Q · filed 2020-11-10 | -$13.45M derived: sum of 4 quarters · filed 2020-11-10 | |
| 2019-06-30 | -$3.36M 10-Q · filed 2020-11-10 | -$6.89M 10-Q · filed 2020-08-06 | -$8.79M derived: sum of 3 quarters · filed 2020-11-10 | -$18.07M derived: sum of 4 quarters · filed 2020-11-10 | |
| 2019-03-31 | -$3.53M 10-Q · filed 2020-11-10 | -$5.44M derived: sum of 2 quarters · filed 2020-11-10 | -$14.71M derived: sum of 3 quarters · filed 2020-11-10 | ||
| 2018-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$11.18M derived: sum of 2 quarters · filed 2020-03-30 | -$12.20M 10-K · filed 2020-03-30 | ||
| 2018-09-30 | -$9.28M 10-Q · filed 2019-12-05 | -$10.30M 10-Q · filed 2019-12-05 | |||
| 2018-06-30 | -$1.02M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |